Sunitinib for advanced pancreatic neuroendocrine tumors

References

• Yao JC, Hassan M, Phan A et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol.26, 3063–3072 (2008).
   PubMed Web of Science ®Google Scholar
• Yao JC, Eisner MP, Leary C et al. Population-based study of islet cell carcinoma. Ann. Surg. Oncol.14, 3492–3500 (2007).
   PubMed Web of Science ®Google Scholar
• Ehehalt F, Saeger HD, Schmidt CM et al. Neuroendocrine tumors of the pancreas. Oncologist14, 456–467 (2009).
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol.27, 4656–4663 (2009).
   PubMed Web of Science ®Google Scholar
• Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol.9, 61–72 (2008).
   PubMed Web of Science ®Google Scholar
• Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med.303, 1189–1194 (1980).
   PubMed Web of Science ®Google Scholar
• Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol.22, 4762–4771 (2004).
   PubMed Web of Science ®Google Scholar
• Kulke MH, Stuart K, Enzinger PC et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol.24, 401–406 (2006).
   PubMed Web of Science ®Google Scholar
• Turner NC, Strauss SJ, Sarker D et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br. J. Cancer102, 1106–1112 (2010).
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res.9, 327–337 (2003).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet368, 1329–1338 (2006).
   PubMed Web of Science ®Google Scholar
• Sun L, Liang C, Shirazian S et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem.46, 1116–1119 (2003).
   PubMed Web of Science ®Google Scholar
• Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol. Endocrinol.9, 1760–1770 (1995).
   PubMed Web of Science ®Google Scholar
• Terris B, Scoazec JY, Rubbia L et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology32, 133–138 (1998).
   PubMed Web of Science ®Google Scholar
• Turner HE, Harris AL, Melmed S et al. Angiogenesis in endocrine tumors. Endocr. Rev.24, 600–632 (2003).
   PubMed Web of Science ®Google Scholar
• La Rosa S, Uccella S, Finzi G et al. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum. Pathol.34, 18–27 (2003).
   PubMed Web of Science ®Google Scholar
• Inoue M, Hager JH, Ferrara N et al. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell1(2), 193–202 (2002).
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell8, 299–309 (2005).
   PubMed Web of Science ®Google Scholar
• Albrecht I, Kopfstein L, Strittmatter K et al. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One5, e14109 (2010).
   PubMed Web of Science ®Google Scholar
• Chaudhry A, Papanicolaou V, Oberg K et al. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res.52, 1006–1012 (1992).
   PubMed Web of Science ®Google Scholar
• Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose ‘chemo-switch’ regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol.23, 939–952 (2005).
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest.111, 1287–1295 (2003).
   PubMed Web of Science ®Google Scholar
• Koch CA, Gimm O, Vortmeyer AO et al. Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy? Ann. NY Acad. Sci.1073, 517–526 (2006).
   PubMed Web of Science ®Google Scholar
• Chow LQ, Eckhardt SG: Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol.25, 884–896 (2007).
   PubMed Web of Science ®Google Scholar
• Osusky KL, Hallahan DE, Fu A et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis7, 225–233 (2004).
   PubMedGoogle Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Podar K, Tonon G, Sattler M et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl Acad. Sci. USA103, 19478–19483 (2006).
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther.295, 139–145 (2000).
   PubMed Web of Science ®Google Scholar
• Baratte S, Sarati S, Frigerio E et al. Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J. Chromatogr. A.1024, 87–94 (2004).
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Foran JM, Fiedler W et al. An innovative Phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res.9, 5465–5476 (2003).
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol.24, 25–35 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Escudier B, Roigas J, Gillessen S et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J. Clin. Oncol.27, 4068–4075 (2009).
   PubMed Web of Science ®Google Scholar
• Deprimo SE, Bello CL, Smeraglia J et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med.5, 32 (2007).
   PubMed Web of Science ®Google Scholar
• George S, Blay JY, Casali PG et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur. J. Cancer45, 1959–1968 (2009).
   PubMed Web of Science ®Google Scholar
• Novello S, Scagliotti GV, Rosell R et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br. J. Cancer101, 1543–1548 (2009).
   PubMed Web of Science ®Google Scholar
• Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol.26, 3403–3410 (2008).
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92, 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Hobday TJ, Rubin J, Holen K et al. MC044h, a Phase II trial of sorafenib in patients with metastatic neuroendocrine tumours (NET): a Phase II Consortium (P2C) study. J. Clin. Oncol.25, 199s (2007) (Abstract 4504).
   Google Scholar
• Phan AT, Yao JC, Fogelman DR et al. A prospective, multi-institutional Phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J. Clin. Oncol.28, 301s (2010) (Abstract 4001).
   Google Scholar
• Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med.364, 501–513 (2011).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Seitz JF, Raoul JL et al. Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumours treated with sunitinib or placebo. J. Clin. Oncol.29(Suppl. 4), (2011) (Abstract 219).
   Google Scholar
• Raymond E, Niccoli P, Raoul JL et al. Updated overall survival and progression-free survival by blinded independent central review of sunitinib versus placebo for patients with advanced unresectable pancreatic neuroendocrine tumours. J. Clin. Oncol.29 (2011) (Abstract 4008).
   Web of Science ®Google Scholar
• Desai J, Dileo P, Morgan JA et al. Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy. J. Clin. Oncol.23, 201s (2005) (Abstract 3040).
   Google Scholar
• Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst.99, 81–83 (2007).
   PubMed Web of Science ®Google Scholar
• Sutent®, Summary of product characteristics. Pfizer Ltd, NY, USA (2010).
   Google Scholar
• Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med.364, 514–523 (2011).
   PubMed Web of Science ®Google Scholar
• Missiaglia E, Dalai I, Barbi S et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol.28, 245–255 (2010).
   PubMed Web of Science ®Google Scholar
• von Wichert G, Jehle PM, Hoeflich A et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res.60, 4573–4581 (2000).
   PubMed Web of Science ®Google Scholar
• Zitzmann K, De Toni EN, Brand S et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology85, 54–60 (2007).
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a Phase II trial. J. Clin. Oncol.28, 69–76 (2010).
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan AT, Fogelman DR et al. Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumours (LGNETs) using perfusion CT as functional biomarker. J. Clin. Oncol.28 (2010) (Abstract 4002).
   Web of Science ®Google Scholar
• Kunz PL, Kuo T, Zahn JM et al. A Phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J. Clin. Oncol.28 (2010) (Abstract 41040).
   Web of Science ®Google Scholar
• Kulke MH, Siu LL, Tepper JE et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J. Clin. Oncol.29, 934–943 (2011).
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T et al. Phase III randomised trial of everolimus (RAD001) vs placebo in advanced pancreatic NET (RADIANT-3). Presented at: 35th ESMO Congress. Milan, Italy, 8–11 October 2010 (Abstract LBA9).
   Google Scholar